Effects of fullerenol C60 on hepatic ischemia-reperfusion injury in desflurane-anesthetized rats
WORLD JOURNAL OF HEPATOLOGY, cilt.18, sa.9, 2026 (ESCI, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 18 Sayı: 9
- Basım Tarihi: 2026
- Doi Numarası: 10.4254/wjh.122845
- Dergi Adı: WORLD JOURNAL OF HEPATOLOGY
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
- Gazi Üniversitesi Adresli: Evet
Özet
BACKGROUND Hepatic ischemia-reperfusion injury (IRI) occurs in various clinical settings, including liver surgery, transplantation, trauma, hemorrhagic shock, and temporary vascular occlusion. It is associated with oxidative stress, inflammation, and hepatocellular injury. Desflurane is an inhalational anesthetic, and fullerenol C60 is a carbon-derived compound investigated for possible tissue-protective effects. AIM To evaluate their effects on hepatic IRI in rats. METHODS Thirty rats were randomly divided into five groups (n = 6 each): Control, IRI, IRI + fullerenol C60 (IRI-F), IRI + desflurane, and IRI-F + desflurane (IRI-F-D). Hepatic ischemia was induced for 120 minutes, followed by 120 minutes of reperfusion. Fullerenol C60 (100 mg/kg, intraperitoneally) was administered 30 minutes before ischemia, and desflurane (6%) was administered during the ischemia-reperfusion period. Malondialdehyde (MDA) levels and catalase (CAT), glutathione-S-transferase (GST), and arylesterase (ARE) activities were measured. Histopathological examination included assessment of hepatocyte degeneration, sinusoidal dilatation, pyknotic nuclei, necrotic cells, and parenchymal mononuclear cell infiltration. RESULTS MDA levels were significantly higher in the IRI group than in the control group (0.25 +/- 0.01 nmol/mg protein vs 0.10 +/- 0.01 nmol/mg protein, P < 0.0001), whereas all treatment groups showed significantly lower MDA levels than the IRI group. CAT, GST, and ARE activities were significantly reduced in the IRI group but improved in the treatment groups (P < 0.0001 for all). Histopathological analysis demonstrated significant intergroup differences in hepatocyte degeneration (P = 0.003), sinusoidal dilatation (P = 0.018), pyknotic nuclei (P = 0.031), and mononuclear cell infiltration (P = 0.003). The most severe injury was observed in the IRI group, whereas fullerenol-treated groups showed marked improvement. Necrotic cell counts did not differ significantly among groups (P = 0.113). CONCLUSION Fullerenol C60 attenuated hepatic IRI by reducing lipid peroxidation, preserving antioxidant enzyme activity, and improving histopathological findings. Desflurane also exerted protective effects. However, direct pairwise comparisons between the IRI-F and IRI-F-D groups showed no statistically significant differences in any biochemical or histopathological parameter, indicating that combined treatment did not provide a significant additional benefit over fullerenol C60 alone (all P > 0.05). Fullerenol C60 may represent a promising adjunctive approach for reducing hepatic injury associated with ischemia-reperfusion.